Pharvaris (NASDAQ:PHVS) CEO Sells $647,257.42 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 23,333 shares of the business’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.74, for a total value of $647,257.42. Following the completion of the transaction, the chief executive officer owned 142,084 shares in the company, valued at approximately $3,941,410.16. This trade represents a 14.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $26.63 on Monday. The firm has a market cap of $1.74 billion, a P/E ratio of -7.90 and a beta of -2.58. Pharvaris N.V. has a fifty-two week low of $11.66 and a fifty-two week high of $29.85. The business has a 50-day moving average price of $27.05 and a 200 day moving average price of $25.53.

Pharvaris News Summary

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Wolfe Research initiated coverage with an “Outperform” rating and a $42 price target (~58% upside vs. current levels), which can boost investor interest and buying pressure. Wolfe Research initiates coverage of Pharvaris NV (PHVS) with outperform recommendation
• Positive Sentiment: Wedbush raised its price target on PHVS to $42, aligning with other bullish voices and reinforcing the street’s constructive view on Pharvaris’ growth/valuation runway. Wedbush Increases Pharvaris (NASDAQ:PHVS) Price Target to $42.00
• Neutral Sentiment: HC Wainwright published earnings/long‑term model commentary for Pharvaris (estimating FY2030 figures and Q1 outlook). Analyst model updates can influence expectations but are not an immediate catalyst absent new clinical or commercial data. HC Wainwright Predicts Pharvaris FY2030 Earnings
• Neutral Sentiment: Reported short-interest data is effectively zero (no measurable short volume), so short-covering or squeeze dynamics are unlikely to be a driver in the near term. (Internal reporting entry.)
• Negative Sentiment: CEO Berndt Modig sold 23,333 shares (~14.1% reduction in his reported position) under a pre-arranged Rule 10b5-1 plan for proceeds ~ $647k. Insider sales can be interpreted negatively by some investors even when executed under 10b5-1 plans. SEC filing for insider sale

Hedge Funds Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently bought and sold shares of PHVS. Wellington Management Group LLP acquired a new position in Pharvaris in the third quarter valued at approximately $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after acquiring an additional 772,583 shares during the period. Balyasny Asset Management L.P. acquired a new position in Pharvaris in the third quarter valued at approximately $15,613,000. Commodore Capital LP boosted its stake in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock valued at $60,341,000 after acquiring an additional 507,043 shares during the period. Finally, General Atlantic L.P. boosted its stake in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after acquiring an additional 500,000 shares during the period.

Analysts Set New Price Targets

Several analysts recently weighed in on PHVS shares. Royal Bank Of Canada lowered their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a report on Thursday. They issued an “outperform” rating and a $42.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Wall Street Zen lowered Pharvaris from a “sell” rating to a “strong sell” rating in a report on Monday. Eleven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $42.73.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.